NCT02608229View on ClinicalTrials.gov

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 6, 2016

Primary Completion Date

March 27, 2019

Study Completion Date

May 21, 2020

Conditions
Pancreatic CancerCancer of PancreasCancer of the PancreasPancreas Cancer
Interventions
DRUG

BVD-523

DRUG

Nab-paclitaxel

DRUG

Gemcitabine

PROCEDURE

Tumor biopsy

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

BioMed Valley Discoveries, Inc

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT02608229 - BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter